Jeffrey Hoch
Names
| first: |
Jeffrey |
| last: |
Hoch |
Identifer
Contact
Affiliations
-
University of California-Davis
/ School of Medecine
/ Department of Public Health Sciences
/ Division of Health Policy and Management
Research profile
author of:
- Measuring and illustrating statistical evidence in a cost-effectiveness analysis (RePEc:eee:jhecon:v:27:y:2008:i:2:p:476-495)
by Hoch, Jeffrey S. & Blume, Jeffrey D. - Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control (RePEc:eee:socmed:v:122:y:2014:i:c:p:130-139)
by Regier, Dean A. & Bentley, Colene & Mitton, Craig & Bryan, Stirling & Burgess, Michael M. & Chesney, Ellen & Coldman, Andy & Gibson, Jennifer & Hoch, Jeffrey & Rahman, Syed & Sabharwal, Mona & Sawka, - Labs and cases in health insurance and cost-effectiveness analyses to enhance active learning experiences in an introductory healtheconomics course for students in health professions (RePEc:elg:eechap:19244_4)
by Carolyn S. Dewa & Jeffrey S. Hoch - Using net benefit regression to teach cost-effectiveness analysis with a dataset (RePEc:elg:eechap:19244_6)
by Jeffrey S. Hoch & Carolyn S. Dewa - Econometric Considerations When Using the Net Benefit Regression Framework to Conduct Cost-effectiveness Analysis (RePEc:eme:ceazzz:s0573-855520180000294007)
by Jeffrey S. Hoch & Pierre Chaussé - Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors (RePEc:plo:pone00:0152944)
by Carolyn S Dewa & Lucy Trojanowski & Sietske J Tamminga & Jolie Ringash & Maurene McQuestion & Jeffrey S Hoch - Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening (RePEc:plo:pone00:0172864)
by S Lucas Goede & Linda Rabeneck & Marjolein van Ballegooijen & Ann G Zauber & Lawrence F Paszat & Jeffrey S Hoch & Jean H E Yong & Sonja Kroep & Jill Tinmouth & Iris Lansdorp-Vogelaar - A Review and Meta-analysis of Colorectal Cancer Utilities (RePEc:sae:medema:v:34:y:2014:i:6:p:809-818)
by Sandjar Djalalov & Linda Rabeneck & George Tomlinson & Karen E. Bremner & Robert Hilsden & Jeffrey S. Hoch - Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation (RePEc:spr:aphecp:v:14:y:2016:i:3:d:10.1007_s40258-016-0229-2)
by Amy Tawfik & Walter P. Wodchis & Petros Pechlivanoglou & Jeffrey Hoch & Don Husereau & Murray Krahn - Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario (RePEc:spr:isochp:978-1-4614-6507-2_18)
by Jeffrey S. Hoch - Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions (RePEc:spr:pharme:v:25:y:2007:i:10:p:807-816)
by Jeffrey Hoch & Carolyn Dewa - The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada (RePEc:spr:pharme:v:31:y:2013:i:3:p:229-236)
by Jean Yong & Jaclyn Beca & Jeffrey Hoch - Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters (RePEc:spr:pharme:v:33:y:2015:i:10:p:1083-1090)
by Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch - Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? (RePEc:spr:pharme:v:33:y:2015:i:8:p:879-882)
by Jeffrey Hoch & Jaclyn Beca & Mona Sabharwal & Scott Livingstone & Anthony Fields - Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment (RePEc:spr:pharme:v:36:y:2018:i:1:d:10.1007_s40273-017-0583-4)
by Jaclyn Beca & Don Husereau & Kelvin K. W. Chan & Neil Hawkins & Jeffrey S. Hoch - A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis (RePEc:spr:pharme:v:37:y:2019:i:12:d:10.1007_s40273-019-00830-4)
by Sandjar Djalalov & Jaclyn Beca & Emmanuel M. Ewara & Jeffrey S. Hoch - Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology (RePEc:spr:pharmo:v:1:y:2017:i:3:d:10.1007_s41669-017-0022-7)
by Kavisha Jayasundara & Murray Krahn & Muhammad Mamdani & Jeffrey S. Hoch & Paul Grootendorst - Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR) (RePEc:spr:pharmo:v:1:y:2017:i:4:d:10.1007_s41669-017-0018-3)
by Lisa Masucci & Jaclyn Beca & Mona Sabharwal & Jeffrey S. Hoch - The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study (RePEc:spr:pharmo:v:2:y:2018:i:3:d:10.1007_s41669-017-0051-2)
by Malek B. Hannouf & Eric Winquist & Salaheddin M. Mahmud & Muriel Brackstone & Sisira Sarma & George Rodrigues & Peter K. Rogan & Jeffrey S. Hoch & Gregory S. Zaric - Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom (RePEc:spr:pharmo:v:2:y:2018:i:3:d:10.1007_s41669-018-0083-2)
by David G. T. Whitehurst & Nicholas R. Latimer & Aura Kagan & Rebecca Palmer & Nina Simmons-Mackie & J. Charles Victor & Jeffrey S. Hoch - Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis (RePEc:wly:hlthec:v:11:y:2002:i:5:p:415-430)
by Jeffrey S. Hoch & Andrew H. Briggs & Andrew R. Willan - Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data (RePEc:wly:hlthec:v:13:y:2004:i:5:p:461-475)
by Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch